← 返回

FUDR 的磷酸酰胺酯修饰物 NUC-3373 可引起结直肠癌细胞的 DNA 损伤和 DAMPs 释放,从而增强淋巴细胞诱导的细胞死亡

英文原题:A phosphoramidate modification of FUDR, NUC-3373, causes DNA damage and DAMPs release from colorectal cancer cells, potentiating lymphocyte-induced cell death.

查看英文原题

A phosphoramidate modification of FUDR, NUC-3373, causes DNA damage and DAMPs release from colorectal cancer cells, potentiating lymphocyte-induced cell death.

PubMed 2025/09/16(内容时间) PLoS One Q2 · IF 2.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

结直肠癌(CRC)是全球癌症相关死亡的主要原因之一,5-FU 仍是首选的主要化疗药物。随着免疫疗法的日益广泛应用,大量研究聚焦于使肿瘤更具免疫原性的能力,从而为联合免疫治疗提供依据。

在此,我们研究 NUC-3373——5-氟脱氧尿苷(FUDR)的氨基磷酸酯转化物——是否能增强 CRC 细胞系的免疫原性,并在体外促进淋巴细胞介导的细胞死亡。在低于 IC50 的剂量下,NUC-3373 在 HCT116 和 SW480 细胞中均上调损伤相关分子模式(DAMPs),并增加 MHCII 和 PD-L1 的表面表达。与溶剂对照相比,用 NUC-3373 预处理并随后与 NK-92 MI NK 细胞共培养,导致 LAMP1 表达(脱颗粒)增加、IFN-γ 产生以及 NK 介导的细胞毒性增强。将患者来源的 PBMCs 与经 NUC-3373 预处理的异体 CRC 细胞共培养,与溶剂对照以及暴露于 NUC-3373 的 CRC 细胞单培养相比,均显示出细胞死亡增加。

最后,当 HCT116 细胞用 NUC-3373 预处理时,PD-1 免疫检查点抑制剂 nivolumab 显示出协同活性。

总之,我们表明 NUC-3373 能够调节免疫信号,因此可能在体外促进免疫介导的肿瘤细胞死亡。

展开英文摘要原文

Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality worldwide with 5-FU still the primary chemotherapeutic of choice. With the increasing use of immunotherapies, much research is focused on the ability to make tumours more immunogenic, thereby rationalising combination with immunotherapy.

Here we investigate whether NUC-3373, a phosphoramidate transformation of 5-fluorodeoxyuridine (FUDR), enhances immunogenicity in CRC cell lines and facilitates lymphocyte mediated cell death in vitro. At sub IC50 doses NUC-3373 upregulates damage associate molecular patterns (DAMPs) in both HCT116 and SW480 cells and increases surface expression of MHCII and PD-L1. Pre-treatment with NUC-3373 and subsequent coculture with NK-92 MI natural killer cells caused an increase in LAMP1 expression (degranulation), production of IFN-γ, and NK-mediated cytotoxicity compared to vehicle controls.

Cocultures with patient-derived PBMCs with heterologous CRC cells pre-treated with NUC-3373 demonstrated increased cell death compared to both vehicle controls and monocultures of CRC cells exposed to NUC-3373. Lastly, the PD-1 immune checkpoint inhibitor nivolumab showed synergistic activity when HCT116 cells were pre-treated with NUC-3373. To conclude, we show that NUC-3373 can modulate immune signaling and may therefore facilitate immune mediated tumour cell death in vitro.

论文信息

作者
Read OJ、Bré J、Zhang Y、Mullen P、Elshani M、Harrison DJ
单位
School of Medicine, University of St Andrews, St Andrews, United Kingdom.United Kingdom
期刊
PloS one2025
原文标识
PubMed 40956795 · DOI 10.1371/journal.pone.0331567